SV2002000440A - Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb - Google Patents
Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bbInfo
- Publication number
- SV2002000440A SV2002000440A SV2001000440A SV2001000440A SV2002000440A SV 2002000440 A SV2002000440 A SV 2002000440A SV 2001000440 A SV2001000440 A SV 2001000440A SV 2001000440 A SV2001000440 A SV 2001000440A SV 2002000440 A SV2002000440 A SV 2002000440A
- Authority
- SV
- El Salvador
- Prior art keywords
- disease
- inhibitor
- procedure
- treatment
- cognitive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE TRATAMIENTO DE ENFERMEDADES DE DISFUNSION COGNITIVA EN UN MAMIFERO, QUE COMPRENDE LA ADMINISTRACION DE UN AGONISTA PARCIAL DEL RECEPTOR DE NICOTINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; Y UN INHIBIDOR DE ACETILCOLINESTRA, UN INHIBIDOR DE BUTILCOLINESTERASA, UN AGENTE ENTROGENICO, UN MODULADOR SELECTIVO DEL RECEPTOR DE ESTREOGENOS O UN AGONISTA MUSCARINICO, O UNA SAL FARMACEUTICAMENTE ACEPTABLE. EL AGONISTA PARCIAL DEL RECEPTOR DE NICOTINA Y EL INHIBIDOR DE ACETILCOLINESTERASA, EL INHIBIDOR DE BUTILCOLINESTERASA, EL ESTROGENO, EL MODULADOR SELECTIVO DEL RECEPTOR DE ESTROGENOS O EN ANTAGONISTA MUSCARINICO ESTAN PRESENTES EN CANTIDADES QUE HACEN A LA COMPOSICION EFICAZ EN LA POTENCIACION DE LA COGNICION O EN EL TRATAMIENTO DE ENFERMEDADES DE DISFUNCION COGNITIVA QUE INCLUYEN, PERO SIN LIMITACION, LA ENFERMEDAD DE ALZHEIMER, DETERIORO COGNITIVO LEVE, DISMINUCION COGNITIVA RELACIONADAD CON LA EDAD, DEMENCIA VASCULAR, DEMENCIA POR ENFERMEDAD DE PARKINSON, ENFERMEDAD DE HUNTINGTON, APOPLEJIA, TBI, DEMENCIA ASOCIADA CON EL SIDA Y ESQUIZOFRENIA. TAMBIEN SE DESCRIBE EL PROCEDIMIENTO DE USO DE ESTAS COMPOSICIONES
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20279900P | 2000-05-09 | 2000-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2002000440A true SV2002000440A (es) | 2002-10-24 |
Family
ID=22751325
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2001000440A SV2002000440A (es) | 2000-05-09 | 2001-05-08 | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb |
Country Status (16)
Country | Link |
---|---|
US (2) | US20010036949A1 (es) |
EP (1) | EP1280554A2 (es) |
JP (1) | JP2003532670A (es) |
AR (1) | AR028426A1 (es) |
AU (1) | AU2001248699A1 (es) |
BR (1) | BR0110487A (es) |
CA (1) | CA2409720A1 (es) |
EC (1) | ECSP014065A (es) |
GT (1) | GT200100075A (es) |
MX (1) | MXPA02011051A (es) |
PA (1) | PA8516701A1 (es) |
PE (1) | PE20011256A1 (es) |
SV (1) | SV2002000440A (es) |
TN (1) | TNSN01068A1 (es) |
UY (1) | UY26693A1 (es) |
WO (1) | WO2001085145A2 (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050063998A1 (en) * | 1999-10-26 | 2005-03-24 | Francois Marc Karel Jozef | Oral solution containing galantamine and a sweetening agent |
US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
US20030153598A1 (en) * | 2000-07-25 | 2003-08-14 | Raymond Pratt | Methods for treating Parkinson's disease with cholinesterase inhibitors |
PT1311272E (pt) | 2000-03-03 | 2007-02-28 | Eisai R&D Man Co Ltd | Novos métodos utilizando inibidores de colinesterase |
BR0208992A (pt) * | 2001-04-20 | 2004-04-27 | Pfizer Prod Inc | Processo para a preparação de indenos 1,3-substituìdos e compostos azapolicìclicos fundidos com arila |
AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
US20040006092A1 (en) * | 2001-08-31 | 2004-01-08 | Neurochem, Inc. | Amidine derivatives for treating amyloidosis |
WO2004028634A1 (en) * | 2002-09-25 | 2004-04-08 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating alzheimer's disease and dementias of vascular origin |
WO2005000806A2 (en) * | 2003-06-10 | 2005-01-06 | Georgetown University | Ligands for nicotinic acetylcholine receptors, and methods of making and using them |
US8299062B2 (en) * | 2003-09-17 | 2012-10-30 | Franklin Volvovitz | Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction |
NZ593444A (en) | 2003-10-01 | 2012-12-21 | Adolor Corp | 4-[(2-N,N-diethylaminocarbonyl)pyrid-5-yl]-spiro[1,2-dihydronaphthalene-2,4'-piperidine] and methods of its use |
US20060019938A1 (en) * | 2003-12-31 | 2006-01-26 | Beer Tomasz M | Estrogen administration for treating male cognitive dysfunction or improving male cognitive function |
US7262223B2 (en) * | 2004-01-23 | 2007-08-28 | Neurochem (International) Limited | Amidine derivatives for treating amyloidosis |
US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
WO2005112908A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function |
AU2005247948A1 (en) * | 2004-05-27 | 2005-12-08 | Migenix Corp. | 2-substituted 17-imino estrogen compounds for cytoprotection |
EP2258359A3 (en) * | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
CA2620333A1 (en) * | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
US7576207B2 (en) | 2006-04-06 | 2009-08-18 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
GB0607952D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res Ltd | Novel treatment |
GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
WO2008033299A2 (en) | 2006-09-12 | 2008-03-20 | Adolor Corporation | Use of n-containing spirocompounds for the enhancement of cognitive function |
WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
FR2931677B1 (fr) * | 2008-06-02 | 2010-08-20 | Sanofi Aventis | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs |
EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
JP6082250B2 (ja) | 2010-02-09 | 2017-02-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 認知機能を改善するための方法および組成物 |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
US8349376B1 (en) | 2011-03-08 | 2013-01-08 | Bezzek Mark S | Anti-dementia regimen |
US8846061B1 (en) | 2011-03-08 | 2014-09-30 | Mark S. Bezzek | Multivitamin-mineral regimens for longevity and wellness |
DK2686313T3 (en) | 2011-03-16 | 2016-05-02 | Probiodrug Ag | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
WO2012142039A1 (en) * | 2011-04-15 | 2012-10-18 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
EP2968220B1 (en) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6218383B1 (en) * | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
-
2001
- 2001-01-16 US US09/760,966 patent/US20010036949A1/en not_active Abandoned
- 2001-04-24 MX MXPA02011051A patent/MXPA02011051A/es unknown
- 2001-04-24 WO PCT/IB2001/000681 patent/WO2001085145A2/en not_active Application Discontinuation
- 2001-04-24 CA CA002409720A patent/CA2409720A1/en not_active Abandoned
- 2001-04-24 EP EP01921733A patent/EP1280554A2/en not_active Withdrawn
- 2001-04-24 BR BR0110487-0A patent/BR0110487A/pt not_active IP Right Cessation
- 2001-04-24 AU AU2001248699A patent/AU2001248699A1/en not_active Abandoned
- 2001-04-24 JP JP2001581799A patent/JP2003532670A/ja active Pending
- 2001-05-04 GT GT200100075A patent/GT200100075A/es unknown
- 2001-05-07 UY UY26693A patent/UY26693A1/es not_active Application Discontinuation
- 2001-05-08 PE PE2001000412A patent/PE20011256A1/es not_active Application Discontinuation
- 2001-05-08 AR ARP010102169A patent/AR028426A1/es unknown
- 2001-05-08 TN TNTNSN01068A patent/TNSN01068A1/fr unknown
- 2001-05-08 EC EC2001004065A patent/ECSP014065A/es unknown
- 2001-05-08 SV SV2001000440A patent/SV2002000440A/es not_active Application Discontinuation
- 2001-05-09 PA PA20018516701A patent/PA8516701A1/es unknown
-
2003
- 2003-01-21 US US10/347,955 patent/US20030130303A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20030130303A1 (en) | 2003-07-10 |
JP2003532670A (ja) | 2003-11-05 |
PE20011256A1 (es) | 2001-12-29 |
PA8516701A1 (es) | 2002-09-17 |
WO2001085145A8 (en) | 2001-12-13 |
TNSN01068A1 (fr) | 2005-11-10 |
US20010036949A1 (en) | 2001-11-01 |
ECSP014065A (es) | 2003-01-13 |
BR0110487A (pt) | 2003-04-01 |
MXPA02011051A (es) | 2003-03-10 |
UY26693A1 (es) | 2001-12-28 |
GT200100075A (es) | 2001-12-31 |
WO2001085145A2 (en) | 2001-11-15 |
EP1280554A2 (en) | 2003-02-05 |
WO2001085145A3 (en) | 2002-06-13 |
CA2409720A1 (en) | 2001-11-15 |
AU2001248699A1 (en) | 2001-11-20 |
AR028426A1 (es) | 2003-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2002000440A (es) | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb | |
CR7059A (es) | USO DE AGONISTAS INVERSOS DE GABAa EN COMBINACION CON AGONISTAS PARCIALES DEL RECEPTOR DE NICOTINA, ESTROGENOS, MODULADORES SELECTIVOS DE ESTROGENOS O VITAMINA E PARA EL TRAMIENTO DE TRASTORNOS COGNITIVOS | |
EE200300033A (et) | Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon | |
AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
ATE391708T1 (de) | Verbindungen und gemische zur verabreichung eines aktiven agens | |
HUP0301892A2 (hu) | Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk | |
PA8591701A1 (es) | Derivados de pirrolopirimidina | |
HUP0101543A2 (hu) | Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények | |
MA28009A1 (fr) | Derives de pyridazine et utilisation de ceux-ci en tant qu'agents therapeutiques | |
TNSN97044A1 (fr) | Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant. | |
BR0313148A (pt) | Formulações de liberação controlada compreendendo lamotrigina | |
ITFI20030058A1 (it) | Formulazioni farmaceutiche contenenti tiazolidinedioni | |
SE0102055D0 (sv) | New Compounds | |
TNSN01175A1 (fr) | Derives de piperidines antagonistes selectives de sous- types de recepteurs de nmda, et compositions les contenant. | |
MXPA01008993A (es) | Tratamiento de combinacion para depresion y ansiedad. | |
SE0002729D0 (sv) | Novel compound form | |
TNSN04034A1 (en) | Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof | |
BR0104345A (pt) | Tratamento combinado para a depressão e ansiedade | |
ES2113533T3 (es) | Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal. | |
HRP20090225T1 (en) | Pharmaceutical compositions based on nk2 antagonists for pediatric use | |
MXPA05011476A (es) | Imidazolin-2-il-aminofenil-amidas como antagonistas de prostaglandina i2. | |
DE50202865D1 (de) | Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
PA8471901A1 (es) | Derivados de 2"-desoxi higromicina | |
MY131159A (en) | New pharmaceutical compositions containing epinastine and pseudoephedrine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |